Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14028859 | 1.00 | TBXAS1 (0.53) | TBXAS1GPR84TLR7CHRM4CHRM5 | |
| SCHEMBL22788407 | 1.00 | TBXAS1 (0.53) | TBXAS1GPR84TLR7CHRM4CHRM5 | |
| SCHEMBL19334044 | 1.00 | TBXAS1 (0.53) | TBXAS1GPR84TLR7CHRM4CHRM5 | |
| SCHEMBL19441267 | 0.98 | TBXAS1 (0.50) | TBXAS1TLR7CHRM4CHRM5CHRM1 | |
| SCHEMBL4301227 | 0.92 | TBXAS1 (0.44) | TBXAS1CHRM4CHRM5CHRM1CYP2C9 | |
| Hydrochloric Acid SCHEMBL26696161 | 0.90 | TBXAS1 (0.42) | TBXAS1CHRM4CHRM5CHRM1CYP2C9 | |
| SCHEMBL4300091 | 0.84 | — | — | |
| SCHEMBL30427391 | 0.81 | TBXAS1 (0.46) | TBXAS1GPR84TLR7CHRM5CHRM1 | |
| SCHEMBL28879031 | 0.81 | TBXAS1 (0.50) | TBXAS1GPR84TLR7TDP1L3MBTL1 | |
| SCHEMBL30428346 | 0.81 | TBXAS1 (0.46) | TBXAS1GPR84TLR7CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | TNF, HLA-DRB1, GSTK1 | TBXAS1 1112/4885GPR84 3038/4885TLR7 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.